Tumour Immunology What happens when Good Cells go

  • Slides: 27
Download presentation
Tumour Immunology: What happens when Good Cells go Bad.

Tumour Immunology: What happens when Good Cells go Bad.

Host Defense Against Tumor Immunity • Definition coordinated biologic process designed to recognize tumor

Host Defense Against Tumor Immunity • Definition coordinated biologic process designed to recognize tumor cells and their products and to kill or damage the offending cells.

Causative agents Spontaneous UV and ionizing radiation Chemical carcinogens Tumour induction Genetic abnormalities (XP)

Causative agents Spontaneous UV and ionizing radiation Chemical carcinogens Tumour induction Genetic abnormalities (XP) Virus-induced (Hep. C, EBV, HPV) Immunosuppression

Host Defense Against Tumor Immunity • Tumor Specific Antigens (TSA) Present only on tumor

Host Defense Against Tumor Immunity • Tumor Specific Antigens (TSA) Present only on tumor cells and not on any normal cells and can be recognized by cytotoxic T-lymphocytes. • Tumor Associated Antigens (TAA) Not unique to tumors and are also see on normal cells.

Tumor Antigens • Tumor Specific Antigens (TSA) Ø Cancer testis antigen Ø Viral antigen

Tumor Antigens • Tumor Specific Antigens (TSA) Ø Cancer testis antigen Ø Viral antigen Ø Mucin Ø Oncofetal antigens Ø Antigens resulting from mutational in protein Ø B catenin, RAS, P 53, CDK 4

Tumor Antigens • Tissue Associated Antigen=TAA Present in normal cells & tumor cells e.

Tumor Antigens • Tissue Associated Antigen=TAA Present in normal cells & tumor cells e. g. MART-1, gp 100, tyrosinase expressed in melanomas & normal melanocytes T-cells directed against melanomas will also destroy normal melanin containing cells

Tumor Antigens Tumor Associated Antigens(TAA) • MART-1, gp 100, tyrosinase • Over expressed antigens

Tumor Antigens Tumor Associated Antigens(TAA) • MART-1, gp 100, tyrosinase • Over expressed antigens • Differentiation- specific antigens

Tumor Associated Antigens(TAA) • Over expressed Antigens e. g HER-2 (neu) in 30 %

Tumor Associated Antigens(TAA) • Over expressed Antigens e. g HER-2 (neu) in 30 % Breast cancer ( present in normal breast & ovary)

Tumor Associated Antigens(TAA) • Differentiation- Specific Antigens e. g CD 10& PSA Expressed in

Tumor Associated Antigens(TAA) • Differentiation- Specific Antigens e. g CD 10& PSA Expressed in normal B cells & Prostate Used as a marker for tumors arise from these cells

How do cancer cells differ from normal? • Clonal in origin • Deregulated growth

How do cancer cells differ from normal? • Clonal in origin • Deregulated growth and lifespan • Altered tissue affinity • Resistance to control via apoptotic signals • Change in surface phenotype and markers • Structural and biochemical changes • Presence of tumour-specific antigens

Immune Surveillance of Cancer • Proposed originally in 1909 by Paul Ehrlich • Refined

Immune Surveillance of Cancer • Proposed originally in 1909 by Paul Ehrlich • Refined in late 1950 s by Burnet and Thomas “In animals…genetic changes must be common and a proportion…will represent a step towards malignancy. …there should be some mechanism for eliminating such potentially dangerous mutant cells and it is postulated that this mechanism is of immunological character. ” FM Burnet “The concept of immunological surveillance” (1970)

Immune Surveillance of Cancer • Subsequent evidence against immune surveillance, particularly from nude mice

Immune Surveillance of Cancer • Subsequent evidence against immune surveillance, particularly from nude mice studies. • More recent studies identify effector populations and KO models utilised. • Definitive evidence of immune surveillance published by Schreiber et al in 2001

Evidence of Immune Surveillance in Humans • Immunosuppression leads to increased development of viral

Evidence of Immune Surveillance in Humans • Immunosuppression leads to increased development of viral -derived tumours (Kaposi / NHL / HPV). • Organ transplant increases malignant melanoma risk. (0. 3% general paediatric popn. , 4% paediatric transplants) • 3 -fold higher risk of sarcoma. • High TIL presence correlates with improved survival. • NK or γ/δ T cell loss correlates with increased tumour pathogenicity.

NK cell control of cancer in humans • NK / NKT cells in animal

NK cell control of cancer in humans • NK / NKT cells in animal models destroy tumours with down-regulated Class I expression. • Control of haematological malignancy after haplotype -mismatched BM/SC transplant Costello et al (2004) Trends Immunol. • Maintenance of remission in acute leukaemias dependent upon CD 56+/CD 8α+ NK cells Lowdell et al (2002) Br. J. Haematol.

Antigens involved in tumour recognition Tumour-specific antigens Testes-specific antigens • Bcr-abl • CDK-4 /

Antigens involved in tumour recognition Tumour-specific antigens Testes-specific antigens • Bcr-abl • CDK-4 / β-catenin • MAGE 1 -3 • NY-ESO-1 (CML) (melanoma) Differentiation antigens Tumour associated antigens • Tyrosinase (TRP-1/2) • Melan-A (melanoma) • Monoclonal Ab (myeloma) • MUC-1 • α-fetoprotein • Her-2/neu • WT-1 • myeloblastin • Survivin (myeloma etc) (many) (breast) (many) (leukaemias) (many)

How does the adaptive IR target tumours? Tumour cell present Ab / ADCC /

How does the adaptive IR target tumours? Tumour cell present Ab / ADCC / cytokine attack B Th Th cells educate other T/B cells CTL Broken up to release antigens APC recruits T cells able to recognise tumour antigens APC T T CTL recognise and destroy other tumour cells

Effector mechanisms against cancer • Monocyte / macrophage release lytic enzymes and phagocytose necrotic

Effector mechanisms against cancer • Monocyte / macrophage release lytic enzymes and phagocytose necrotic material • Antibody against tumour antigens • Induction of tumour-specific CTL and TIL • Initiation of NK / CTL cytotoxic responses • Release of cytokines / chemokines (TNFα, IFNs etc) and antiangiogenic factors

Direct CTL / NK attack CTL Perforin Granzyme B Fas. L TCR Fas (CD

Direct CTL / NK attack CTL Perforin Granzyme B Fas. L TCR Fas (CD 95) Class I + Ag TUMOUR CELL

IR-Mediated Tumour Elimination NKT γδ T NK NKT NK γδ T CTL NK CD

IR-Mediated Tumour Elimination NKT γδ T NK NKT NK γδ T CTL NK CD 4 CTL NK CTL CXC 10 -12 IFNγ DC Innate IR recognises tumour cell establishment IFNγ DC LN NK cells and other effectors recruited to site by chemokines, which also target tumour growth directly. IFNγ CXC 10 -12 CD 4 MΦ MΦ MΦ Tumour-specific T cells home to tumour site, along with macrophages and other effectors to eliminate tumour cells.

Immunoediting- The Great Escape! • Strong evidence that IR controls and eradicates nascent cancer

Immunoediting- The Great Escape! • Strong evidence that IR controls and eradicates nascent cancer cells • “Immunoediting” eventually produces low antigenicity tumour cells • Pressure from immune system coupled with genomic instability selects for escape

Three Es of Immunoediting Elimination Equilibrium Escape NKT CD 4 NK CTL CD 4

Three Es of Immunoediting Elimination Equilibrium Escape NKT CD 4 NK CTL CD 4 NK Genetic instability / tumour heterogeneity CTL

Evasion Mechanisms

Evasion Mechanisms

How does MM evade the immune response? myeloma cancer cell MM cell release factors

How does MM evade the immune response? myeloma cancer cell MM cell release factors which ‘turn off’ T cells APC recruits CTL specific for myeloma Ag Broken up to release antigens T T T APC T T T cells recognise and destroy other cancer cells

Anti-cancer Therapies and the IR Category Example Effect IR Radiation γ/α BM ablation/ localised

Anti-cancer Therapies and the IR Category Example Effect IR Radiation γ/α BM ablation/ localised X Alkylating Cyclophosphamide DNA X-linking X Anti-metabolites 5 -FU Ara-C/Ara-A Inhibit DNA synthesis X Natural products Taxanes Vinca alkaloids Mycins DNA damage or microtubule inhibitors X Metals Cisplatin arsenicals DNA X-linking and cytotoxicity X New drugs Imatinib Thalidomide Signalling inhibitor +/-

Summary • Cancers are one of the leading causes of death throughout the world.

Summary • Cancers are one of the leading causes of death throughout the world. • Tumours arise from single events (spontaneous / viral / induced) and altered characteristics produce unregulated growth. • Majority of tumours dealt with by IR before development progresses to clinical stage. • Immunoediting leads to development of escape clones. • Established tumours can prevent immune attack in the absence of further triggers.